{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:33:24Z","timestamp":1794483204305,"version":"4.9.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Among patients with chronic myeloid leukemia (CML) aiming for tyrosine kinase inhibitor (TKI) discontinuation, second-generation TKIs (2G-TKIs) are used as one of the first-line therapy options because they induce faster and deeper molecular responses (MR) than imatinib. However, predictors of attaining and sustaining MR4.5 (BCR::ABL1 International Scale [IS] \u22640.0032%) during 2G-TKI therapy remain undefined. We analyzed 431 patients enrolled in the phase 3 Japan Adult Leukemia Study Group CML212 trial comparing nilotinib at 300 mg twice daily (n = 218) and dasatinib at 100 mg once daily (n = 213) as first-line therapy. The objective was to identify predictors of MR4.5 attainment and TKI discontinuation eligibility (TDE). Candidate variables assessed within 6 months included the European Treatment and Outcome Study (EUTOS) Long-Term Survival (ELTS) score; BCR::ABL1 IS at baseline, 3 months, and 6 months; and IS-derived halving times (HT), HT (0-3) and HT (3-6). TDE was defined as \u22653 years of TKI therapy with \u22652 consecutive years of sustained MR4.5. With a median follow-up of 3.0 years, the cumulative incidence of MR4.5 was 46.6%, and 36.3% of patients achieving MR4.5 met TDE criteria. In multivariable models, HT (0-3) (subdistribution hazard ratio [HR], 2.23; 95% confidence interval [CI], 1.09-4.55) and the 6-month IS value (HR, 0.38; 95% CI, 0.31-0.47) were independent predictors of MR4.5 attainment, whereas only the 6-month IS value predicted TDE (odds ratio, 0.37; 95% CI, 0.24-0.56). This study demonstrates that MR at 6 months after TKI initiation has important clinical value in early stratification of MR4.5 attainment and TDE in patients receiving 2G-TKI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019701","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:01:07Z","timestamp":1781204467000},"page":"5683-5691","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-7432","authenticated-orcid":false,"given":"Takaaki","family":"Ono","sequence":"first","affiliation":[{"name":"1Department of Transfusion and Cell Therapy, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-6857","authenticated-orcid":false,"given":"Takashi","family":"Okada","sequence":"additional","affiliation":[{"name":"2Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"4Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-226X","authenticated-orcid":false,"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"5Department of Hematology, International University of Health and Welfare, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Rheumatology, National Hospital Organization Saitama Hospital, Wako City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Kakihana","sequence":"additional","affiliation":[{"name":"8Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"9Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[{"name":"10First Department of Internal Medicine, Kansai Medical University Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[{"name":"11Shin-Yurigaoka General Hospital, Kawasaki City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"12Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"13Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0112-6564","authenticated-orcid":false,"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[{"name":"14Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"16Shubun University, Ichinomiya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Chiba University Hospital, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2028-0209","authenticated-orcid":false,"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"18Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"19Mita Hospital, International University of Health and Welfare, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"20Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"21Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2818-4270","authenticated-orcid":false,"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"22Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"10","key":"2026082510515043900_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026082510515043900_bib2","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2026082510515043900_bib3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026082510515043900_bib4","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"2026082510515043900_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"2026082510515043900_bib6","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026082510515043900_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejh.14328","article-title":"Loss in overall and quality-adjusted life expectancy for patients with chronic- phase chronic myeloid leukemia","volume":"114","author":"Chen","year":"2025","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026082510515043900_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2026082510515043900_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","article-title":"JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN)","volume":"121","author":"Takahashi","year":"2025","journal-title":"Int J Hematol"},{"issue":"8","key":"2026082510515043900_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"6","key":"2026082510515043900_bib11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.31187","article-title":"Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase","volume":"124","author":"Sasaki","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"2026082510515043900_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and &gt;10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026082510515043900_bib13","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026082510515043900_bib14","first-page":"2893","article-title":"The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort","volume":"109","author":"Saugues","year":"2024","journal-title":"Haematologica"},{"issue":"20","key":"2026082510515043900_bib15","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","article-title":"Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study","volume":"8","author":"Matsumura","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026082510515043900_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2026082510515043900_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"2026082510515043900_bib18","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026082510515043900_bib19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2026082510515043900_bib20","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026082510515043900_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41375-025-02540-7","article-title":"Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukaemia","volume":"39","author":"Gong","year":"2025","journal-title":"Leukemia"},{"issue":"7046","key":"2026082510515043900_bib22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"21","key":"2026082510515043900_bib23","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026082510515043900_bib24","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2026082510515043900_bib25","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41375-025-02769-2","article-title":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML","volume":"39","author":"Purhonen","year":"2025","journal-title":"Leukemia"},{"issue":"4","key":"2026082510515043900_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"2026082510515043900_bib27","unstructured":"Takahashi\n              N\n            , MatsumuraI, MinamiY, . Treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: results from JALSG N-STOP216. Paper presented at: EHA2021 Virtual Congress; 11-15 June 2021. E-poster EP667. https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/325427\/naoto.takahashi.treatment-free.remission.in.patients.with.chronic.myeloid.htmlRe."},{"key":"2026082510515043900_bib28","unstructured":"Minami\n              Y\n            , MatsumuraI, TakahashiN, . Treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline dasatinib: results from JALSG D-STOP216. Paper presented at: EHA2021 Virtual Congress; 11-15 June 2021. E-poster EP668. https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/325428\/yosuke.minami.treatment-free.remission.in.patients.with.chronic.myeloid.html."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5683\/2537990\/blooda_adv-2026-019701-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5683\/2537990\/blooda_adv-2026-019701-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:54:19Z","timestamp":1787669659000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5683\/569103\/Early-predictors-of-MR4-5-attainment-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019701","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,14]]}}}